HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and maintained a price target of $27.
September 12, 2023 | 10:25 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $27.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for EyePoint Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100